4
H index
0
i10 index
42
Citations
Katharina Elisabeth Blankart : Citation Profile
Berner Fachhochschule (95% share) | RESEARCH PRODUCTION: 22 Articles 4 Papers RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
13 years (2011 - 2024). Relations with other researchers
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Katharina Elisabeth Blankart. | Is cited by:
| Cites to:
|
Main data
Where Katharina Elisabeth Blankart has published?
| Journals with more than one article published | # docs |
|---|---|
| Health Policy | 7 |
| The European Journal of Health Economics | 3 |
| IJERPH | 2 |
| Medical Decision Making | 2 |
Works by Katharina Elisabeth Blankart:
Year  | Title | Type | Cited |
|---|---|---|---|
| 2021 | A Hard Look at “Soft” Cost‐control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany In: CINCH Working Paper Series (since 2020). [Full Text][Citation analysis] | paper | 0 |
| .() In: . [Full Text][Citation analysis] This paper has nother version. Agregated cites: 0 | paper | ||
| 2023 | Policy as a strategy to innovate in health care? A content analysis of innovation policies in Germany, 1994–2017 In: International Journal of Health Planning and Management. [Full Text][Citation analysis] | article | 0 |
| 2011 | A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention In: Health Policy. [Full Text][Citation analysis] | article | 1 |
| 2012 | A systematic review of coverage decision-making on health technologies—Evidence from the real world In: Health Policy. [Full Text][Citation analysis] | article | 9 |
| 2013 | Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis In: Health Policy. [Full Text][Citation analysis] | article | 4 |
| 2016 | Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia In: Health Policy. [Full Text][Citation analysis] | article | 8 |
| 2016 | Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark In: Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2016 | Dispensing behaviour of pharmacies in prescription drug markets In: Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2024 | The challenges of regulatory pluralism In: Health Policy. [Full Text][Citation analysis] | article | 0 |
| In: . [Full Text][Citation analysis] | article | 0 | |
| In: . [Full Text][Citation analysis] | article | 1 | |
| 2020 | Are patients more adherent to newer drugs? In: Health Care Management Science. [Full Text][Citation analysis] | article | 2 |
| 2022 | The Effects of Off-label Drug Use on Disability and Medical Expenditure In: NBER Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2022 | The effects of off-label drug use on disability and medical expenditure.(2022) In: Ruhr Economic Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
| In: . [Full Text][Citation analysis] | article | 0 | |
| 2013 | Link between Process and Appraisal in Coverage Decisions In: Medical Decision Making. [Full Text][Citation analysis] | article | 0 |
| 2014 | Early Benefit Assessment of Pharmaceuticals in Germany In: Medical Decision Making. [Full Text][Citation analysis] | article | 4 |
| 2014 | Analysing coverage decision-making: opening Pandora’s box? In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 1 |
| 2016 | The diffusion of generics after patent expiry in Germany In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 4 |
| 2018 | The impact of physician-level drug budgets on prescribing behavior In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 4 |
| 2024 | Insurance barriers and inequalities in health care access: evidence from dual practice In: Health Economics Review. [Full Text][Citation analysis] | article | 0 |
| In: . [Full Text][Citation analysis] | article | 0 | |
| 2022 | Arzneimittel: Placebo bei Engpassbekämpfung In: Wirtschaftsdienst. [Full Text][Citation analysis] | article | 0 |
| 2021 | Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe In: REGION. [Full Text][Citation analysis] | article | 1 |
| 2020 | The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany In: Health Economics. [Full Text][Citation analysis] | article | 3 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated February, 4 2025. Contact: CitEc Team